This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

David Tew
Senior Scientific Director, Enzyme Engineering and at Glaxosmithkline Medical Reseach Centre


David Tew is a Senior Scientific Director at GSK. In 2018 David was appointed as The Royal Society Entrepreneur in Residence at Bristol University working with BrisSynBio and the Bristol Biodesign Institute. David held this position until 2022.

David has 35 years of experience in the pharmaceutical industry including early drug discovery, mechanistic enzymology, assay development, reagent generation and the application of Synthetic Biology. Most recently David has been leading a project to apply Synthetic Biology to redesign the manufacture of therapeutic oligonucleotides. This has resulted in a platform approach to therapeutic oligonucleotide synthesis and manufacture that is both scalable and more sustainable than current approaches.

Agenda Sessions

  • A Platform Approach to Manufacturing Single Stranded Oligonucleotides by Enzymatic Assembly